HK1250161B - 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 - Google Patents

6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途

Info

Publication number: HK1250161B
Authority: HK; Hong Kong
Prior art keywords: morpholinyl; pyrazolyl; purine derivatives; pi3k inhibitors; pi3k
Prior art date: 2015-03-30

Application number

HK18109578.1A

Other languages

English (en)

Inventor

Kirandeep Kaur Samby

Yogesh Baban Surase

Sagar Ramdas Amale

Suresh Kumar Gorla

Priyanka Patel

Ashwani Kumar Verma

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-30

Filing date

2018-07-24

Publication date

2020-05-15

2018-07-24 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2020-05-15 Publication of HK1250161B publication Critical patent/HK1250161B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

HK18109578.1A 2015-03-30 2018-07-24 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 HK1250161B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN878DE2015		2015-03-30
PCT/IB2016/051762 WO2016157074A1 (en)	2015-03-30	2016-03-29	6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number	Publication Date
HK1250161B true HK1250161B (zh)	2020-05-15

Family

ID=55854760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18109578.1A HK1250161B (zh)	2015-03-30	2018-07-24	6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途

Country Status (31)

Country	Link
US (1)	US10174035B2 (zh)
EP (1)	EP3277682B1 (zh)
JP (1)	JP6669417B2 (zh)
KR (1)	KR20170131444A (zh)
CN (1)	CN107428756B (zh)
AU (1)	AU2016242080B2 (zh)
BR (1)	BR112017020818A2 (zh)
CA (1)	CA2980517C (zh)
CO (1)	CO2017011020A2 (zh)
CY (1)	CY1122018T1 (zh)
DK (1)	DK3277682T3 (zh)
ES (1)	ES2733505T3 (zh)
HK (1)	HK1250161B (zh)
HR (1)	HRP20190998T1 (zh)
HU (1)	HUE045192T2 (zh)
IL (1)	IL254688B (zh)
LT (1)	LT3277682T (zh)
MX (1)	MX2017012390A (zh)
MY (1)	MY185268A (zh)
PH (1)	PH12017501750A1 (zh)
PL (1)	PL3277682T3 (zh)
PT (1)	PT3277682T (zh)
RS (1)	RS59213B1 (zh)
RU (1)	RU2710549C2 (zh)
SG (1)	SG11201706509QA (zh)
SI (1)	SI3277682T1 (zh)
SM (1)	SMT201900405T1 (zh)
TR (1)	TR201910941T4 (zh)
TW (1)	TWI689508B (zh)
WO (1)	WO2016157074A1 (zh)
ZA (1)	ZA201705530B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10822336B2 (en)	2016-09-29	2020-11-03	Daiichi Sankyo Company, Limited	Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof
CN107163061A (zh) *	2017-04-14	2017-09-15	江西科技师范大学	含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
CN110963955A (zh) *	2018-09-30	2020-04-07	南京富润凯德生物医药有限公司	一种单氟代螺环化合物的合成方法及其中间体
CN111087336A (zh) *	2018-10-24	2020-05-01	南京富润凯德生物医药有限公司	一种双氟代螺环化合物的合成方法及其中间体
CN110577515B (zh) *	2019-09-02	2022-05-17	南通大学	一种4-(氮杂环丁烷-3-基)-1-甲基哌嗪-2-酮二盐酸盐的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4768265B2 (ja)	2002-10-15	2011-09-07	シンタファーマシューティカルズコーポレーション	新規化合物
CA2527079A1 (en)	2003-05-29	2005-01-06	Synta Pharmaceuticals, Corp.	Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB2431156A (en)	2005-10-11	2007-04-18	Piramed Ltd	1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CL2007001167A1 (es) *	2006-04-26	2008-01-25	Genentech Inc	Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
CL2007001166A1 (es) *	2006-04-26	2008-01-25	Piramed Ltd	Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
US20080233127A1 (en)	2007-03-21	2008-09-25	Wyeth	Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2009034386A1 (en)	2007-09-13	2009-03-19	Astrazeneca Ab	Derivatives of adenine and 8-aza-adenine and uses thereof-796
BRPI0817503B8 (pt)	2007-10-05	2021-05-25	Sstarbio Pte Ltd	derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
US20110009403A1 (en)	2007-10-05	2011-01-13	S*Bio Pte Ltd.	2-morpholinylpurines as inhibitors of pi3k
ES2537624T3 (es)	2007-10-26	2015-06-10	F. Hoffmann-La Roche Ag	Derivados purina útiles como inhibidores de la quinasa PI3
US20110098267A1 (en)	2008-02-07	2011-04-28	Synta Pharmaceuticals Corporation	Topical formulations for the treatment of psoriasis
KR20110042153A (ko)	2008-05-30	2011-04-25	제넨테크, 인크.	퓨린 ｐｉ３ｋ 억제 화합물 및 사용 방법
JP2011527342A (ja)	2008-07-07	2011-10-27	エックスカバリーホールディングカンパニーエルエルシー	Ｐｉ３ｋアイソフォーム選択的阻害剤
TWI378933B (en)	2008-10-14	2012-12-11	Daiichi Sankyo Co Ltd	Morpholinopurine derivatives
WO2010114494A1 (en)	2009-04-03	2010-10-07	S*Bio Pte Ltd	8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
WO2010136491A1 (en)	2009-05-27	2010-12-02	F. Hoffmann-La Roche Ag	Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2435438A1 (en) *	2009-05-27	2012-04-04	Genentech, Inc.	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2012005463A (es)	2009-11-12	2012-09-12	Hoffmann La Roche	Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
BR112013000867A2 (pt)	2010-07-14	2016-05-17	Hoffmann La Roche	composto de purina seletivos para delta p110 de pi3k e métodos de uso.
AR082986A1 (es)	2010-09-14	2013-01-23	Exelixis Inc	DERIVADOS DE PURINA COMO INHIBIDORES DE PI3K-d, METODOS PARA SU PREPARACION, FORMULACIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
NZ609448A (en)	2010-12-16	2015-07-31	Hoffmann La Roche	Tricyclic pi3k inhibitor compounds and methods of use
MX343706B (es)	2011-01-31	2016-11-18	Novartis Ag	Derivados heterocíclicos novedosos.
US8653089B2 (en)	2011-02-09	2014-02-18	F. Hoffmann-La Roche Ag	Heterocyclic compounds and methods of use

2016
- 2016-03-29 PT PT16718910T patent/PT3277682T/pt unknown
- 2016-03-29 BR BR112017020818-0A patent/BR112017020818A2/pt not_active IP Right Cessation
- 2016-03-29 CN CN201680019892.7A patent/CN107428756B/zh not_active Expired - Fee Related
- 2016-03-29 ES ES16718910T patent/ES2733505T3/es active Active
- 2016-03-29 SI SI201630267T patent/SI3277682T1/sl unknown
- 2016-03-29 MX MX2017012390A patent/MX2017012390A/es active IP Right Grant
- 2016-03-29 KR KR1020177026959A patent/KR20170131444A/ko not_active Application Discontinuation
- 2016-03-29 TW TW105109845A patent/TWI689508B/zh not_active IP Right Cessation
- 2016-03-29 TR TR2019/10941T patent/TR201910941T4/tr unknown
- 2016-03-29 CA CA2980517A patent/CA2980517C/en not_active Expired - Fee Related
- 2016-03-29 PL PL16718910T patent/PL3277682T3/pl unknown
- 2016-03-29 SG SG11201706509QA patent/SG11201706509QA/en unknown
- 2016-03-29 RS RSP20190941 patent/RS59213B1/sr unknown
- 2016-03-29 AU AU2016242080A patent/AU2016242080B2/en not_active Ceased
- 2016-03-29 US US15/560,466 patent/US10174035B2/en active Active
- 2016-03-29 JP JP2017545934A patent/JP6669417B2/ja active Active
- 2016-03-29 RU RU2017134110A patent/RU2710549C2/ru active
- 2016-03-29 LT LTEP16718910.9T patent/LT3277682T/lt unknown
- 2016-03-29 DK DK16718910.9T patent/DK3277682T3/da active
- 2016-03-29 WO PCT/IB2016/051762 patent/WO2016157074A1/en active Application Filing
- 2016-03-29 HU HUE16718910A patent/HUE045192T2/hu unknown
- 2016-03-29 SM SM20190405T patent/SMT201900405T1/it unknown
- 2016-03-29 EP EP16718910.9A patent/EP3277682B1/en active Active
- 2016-03-29 MY MYPI2017001151A patent/MY185268A/en unknown
2017
- 2017-08-15 ZA ZA2017/05530A patent/ZA201705530B/en unknown
- 2017-09-25 PH PH12017501750A patent/PH12017501750A1/en unknown
- 2017-09-25 IL IL254688A patent/IL254688B/en active IP Right Grant
- 2017-10-27 CO CONC2017/0011020A patent/CO2017011020A2/es unknown
2018
- 2018-07-24 HK HK18109578.1A patent/HK1250161B/zh not_active IP Right Cessation
2019
- 2019-06-03 HR HRP20190998TT patent/HRP20190998T1/hr unknown
- 2019-07-19 CY CY20191100773T patent/CY1122018T1/el unknown

Also Published As

Publication number	Publication date
AU2016242080B2 (en)	2019-09-19
CN107428756A (zh)	2017-12-01
SMT201900405T1 (it)	2019-09-09
KR20170131444A (ko)	2017-11-29
WO2016157074A1 (en)	2016-10-06
RU2017134110A (ru)	2019-04-03
HUE045192T2 (hu)	2019-12-30
MX2017012390A (es)	2018-01-26
IL254688B (en)	2021-03-25
MY185268A (en)	2021-04-30
RU2710549C2 (ru)	2019-12-27
JP2018510146A (ja)	2018-04-12
JP6669417B2 (ja)	2020-03-18
ES2733505T3 (es)	2019-11-29
RS59213B1 (sr)	2019-10-31
SG11201706509QA (en)	2017-09-28
CA2980517A1 (en)	2016-10-06
EP3277682A1 (en)	2018-02-07
EP3277682B1 (en)	2019-04-24
US10174035B2 (en)	2019-01-08
BR112017020818A2 (pt)	2018-07-03
LT3277682T (lt)	2019-06-25
TW201643162A (zh)	2016-12-16
DK3277682T3 (da)	2019-07-29
CN107428756B (zh)	2019-07-23
ZA201705530B (en)	2018-05-30
IL254688A0 (en)	2017-11-30
CO2017011020A2 (es)	2018-01-16
CA2980517C (en)	2020-02-25
US20180072732A1 (en)	2018-03-15
PT3277682T (pt)	2019-07-09
RU2017134110A3 (zh)	2019-06-11
PL3277682T3 (pl)	2019-09-30
HRP20190998T1 (hr)	2019-10-18
TR201910941T4 (tr)	2019-08-21
AU2016242080A1 (en)	2017-08-24
TWI689508B (zh)	2020-04-01
PH12017501750A1 (en)	2018-04-02
CY1122018T1 (el)	2020-10-14
SI3277682T1 (sl)	2019-06-28

Publication	Publication Date	Title
IL278916A (en)	2021-01-31	Benzoimidazole derivatives as PAD4 inhibitors
IL258081B (en)	2022-10-01	Benzimidazole history and their use
IL254318B (en)	2019-08-29	History of benzaimidazoles as bromodomain inhibitors
HK1248520A1 (zh)	2018-10-19	Egfr和pi3k的小分子抑制劑
AP2015008783A0 (en)	2015-10-31	6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
HK1232227A1 (zh)	2018-01-05	作為抑制劑的喹嗪酮衍生物
HK1250161B (zh)	2020-05-15	6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
HK1250926A1 (zh)	2019-01-18	抑制劑及其應用
IL261645A (en)	2018-10-31	History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
PL3362450T3 (pl)	2021-08-23	N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
IL258690A (en)	2018-06-28	Pyridone derivatives and their use as kinase inhibitors
GB201505975D0 (en)	2015-05-20	Inhibitors and their uses
GB201505971D0 (en)	2015-05-20	Inhibitors and their uses
PT3224253T (pt)	2020-01-20	Derivados do bis(sulfonamida) e sua utilização como inibidores de mpges
GB201509381D0 (en)	2015-07-15	Novel compounds and their use as kinase inhibitors
GB201505460D0 (en)	2015-05-13	Novel compounds and their use as kinase inhibitors
GB201409661D0 (en)	2014-07-16	Novel compounds and their use as kinase inhibitors
GB201405532D0 (en)	2014-05-14	Novel compounds and their use as Kinase inhibitors

Legal Events

Date	Code	Title	Description
2024-10-25	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20240328